MX2022003063A - Composiciones terapeuticas, combinaciones y metodos de uso. - Google Patents

Composiciones terapeuticas, combinaciones y metodos de uso.

Info

Publication number
MX2022003063A
MX2022003063A MX2022003063A MX2022003063A MX2022003063A MX 2022003063 A MX2022003063 A MX 2022003063A MX 2022003063 A MX2022003063 A MX 2022003063A MX 2022003063 A MX2022003063 A MX 2022003063A MX 2022003063 A MX2022003063 A MX 2022003063A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
combination
inhibitor
chs
Prior art date
Application number
MX2022003063A
Other languages
English (en)
Inventor
Udai Banerji
Original Assignee
The Institute Of Cancer Res Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute Of Cancer Res Royal Cancer Hospital filed Critical The Institute Of Cancer Res Royal Cancer Hospital
Publication of MX2022003063A publication Critical patent/MX2022003063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a métodos que comprenden la administración de un inhibidor de FAK (por ejemplo, VS-6063) en combinación con un inhibidor dual de RAF/MEK (por ejemplo, CH5126766) que son útiles en el tratamiento del crecimiento celular anormal, como el cáncer, en un sujeto como tal como humanos.
MX2022003063A 2019-09-13 2020-09-11 Composiciones terapeuticas, combinaciones y metodos de uso. MX2022003063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/074565 WO2021047783A1 (en) 2019-09-13 2019-09-13 Vs-6063 in combination with ch5126766 for the treatment of cancer
PCT/EP2020/075455 WO2021048339A1 (en) 2019-09-13 2020-09-11 Vs-6063 in combination with ch5126766 for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2022003063A true MX2022003063A (es) 2022-06-14

Family

ID=67988988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003063A MX2022003063A (es) 2019-09-13 2020-09-11 Composiciones terapeuticas, combinaciones y metodos de uso.

Country Status (10)

Country Link
US (3) US11517573B2 (es)
EP (1) EP4028010A1 (es)
JP (2) JP2022547358A (es)
KR (1) KR20220078606A (es)
CN (1) CN114630667A (es)
AU (1) AU2020344829A1 (es)
BR (1) BR112022004699A2 (es)
CA (1) CA3152805A1 (es)
MX (1) MX2022003063A (es)
WO (3) WO2021047783A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221259A1 (es) * 2019-11-18 2022-08-16 Inxmed Nanjing Co Ltd Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras
CN115052603B (zh) 2020-02-05 2023-12-19 应世生物科技(南京)有限公司 Bi853520与化疗药物的联用
US20230330088A1 (en) * 2020-07-13 2023-10-19 Verastem, Inc. Combination therapy for treating abnormal cell growth
KR20240041978A (ko) * 2021-07-27 2024-04-01 베라스템, 인코포레이티드 비정상적 세포 성장을 치료하기 위한 조합 요법
WO2023020291A1 (zh) 2021-08-16 2023-02-23 应世生物科技(南京)有限公司 In10018与pld的联用
EP4422617A1 (en) * 2021-10-28 2024-09-04 Verastem, Inc. Combination therapy for treating abnormal cell growth
MX2024005253A (es) * 2021-11-02 2024-05-14 Verastem Inc Metodos para tratar crecimiento celular anormal.
WO2023138630A1 (zh) * 2022-01-21 2023-07-27 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN114917232A (zh) * 2022-06-27 2022-08-19 厦门骨本生物科技有限公司 Ch5126766在制备缓解或治疗动物骨关节炎的药物中的应用
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
CN117582504A (zh) * 2022-08-15 2024-02-23 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
CN103951658B (zh) 2007-04-18 2017-10-13 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
WO2011054620A1 (en) 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
WO2013035754A1 (ja) 2011-09-05 2013-03-14 中外製薬株式会社 クマリン誘導体の製造方法
US20150071918A1 (en) 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
NZ702244A (en) 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
RU2015117483A (ru) 2012-10-12 2016-12-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинации
NZ760233A (en) * 2014-01-09 2022-04-29 Pfizer Compositions and methods for treatment of abnormal cell growth
FI3698790T3 (fi) 2014-02-07 2023-06-06 Verastem Inc Menetelmiä epänormaalin solukasvun hoitamiseksi
CN108289892B (zh) 2015-06-29 2021-11-23 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法
BR112020004246A2 (pt) * 2017-09-07 2020-09-01 Revolution Medicines, Inc. composições inibidoras de shp2 e métodos para o tratamento de câncer
WO2019096397A1 (en) 2017-11-16 2019-05-23 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder

Also Published As

Publication number Publication date
US11517573B2 (en) 2022-12-06
WO2021047798A1 (en) 2021-03-18
AU2020344829A1 (en) 2022-03-03
TW202114677A (zh) 2021-04-16
EP4028010A1 (en) 2022-07-20
US20230277535A1 (en) 2023-09-07
US20240197731A1 (en) 2024-06-20
BR112022004699A2 (pt) 2022-06-14
CA3152805A1 (en) 2021-03-18
JP2022547358A (ja) 2022-11-14
CN114630667A (zh) 2022-06-14
KR20220078606A (ko) 2022-06-10
US20220031698A1 (en) 2022-02-03
WO2021048339A1 (en) 2021-03-18
WO2021047783A1 (en) 2021-03-18
JP2022172480A (ja) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2022003063A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
CR20210415A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
ZA201800572B (en) Therapeutic compositions, combinations, and methods of use
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
MX2020010369A (es) Particulas implantables y metodos relacionados.
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
MX2021014286A (es) Proteinas multiespecificas.
PH12020552135A1 (en) Kdm1a inhibitors for the treatment of disease
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
MX2022001004A (es) Inhibidores de enzimas.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
MX2018015410A (es) Esteres de oxaborol y sus usos.
MX2023012048A (es) Composiciones y metodos para inhibir cetohexoquinasa (khk).
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
MX2020007393A (es) Compuestos de fósforo(n)amidatacetal y fosf(on)atalcetal.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
WO2023108110A3 (en) Combination therapy for treating abnormal cell growth
PH12021550035A1 (en) Combination therapy
AU2018319565A1 (en) Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
MX2020009478A (es) Compuestos y sus usos para tratar tumores en un paciente.
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy